| Literature DB >> 25431607 |
Kyoung-Sun Park1, Kang-In Park1, Deok-Sang Hwang1, Jin-Moo Lee1, Jun-Bock Jang1, Chang-Hoon Lee1.
Abstract
Purpose. Primary dysmenorrhea (PD) is a common gynecological complaint among adolescent girls and women of reproductive age. This study aims to review the findings of published articles on the in vitro and in vivo efficacy of herbal medicines for PD. Methods. In vitro and in vivo studies of herbal compounds, individual herbal extracts, or herbal formula decoctions published from their inception to April 2014 were included in this review. Results. A total of 18 studies involving herbal medicines exhibited their inhibitory effect on PD. The majority of in vitro studies investigated the inhibition of uterine contractions. In vivo studies suggest that herbal medicines exert a peripheral analgesic effect and a possible anti-inflammatory activity via the inhibition of prostaglandin (PG) synthesis. The mechanisms of herbal medicines for PD are associated with PG level reduction, suppression of cyclooxygenase-2 expression, superoxide dismutase activation and malondialdehyde reduction, nitric oxide, inducible nitric oxide synthase, and nuclear factor-kappa B reduction, stimulation of somatostatin receptor, intracellular Ca(2+) reduction, and recovery of phospholipid metabolism. Conclusions. Herbal medicines are thought to be promising sources for the development of effective therapeutic agents for PD. Further investigations on the appropriate herbal formula and their constituents are recommended.Entities:
Year: 2014 PMID: 25431607 PMCID: PMC4238180 DOI: 10.1155/2014/296860
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Flow diagram of the study selection process.
In vitro studies of herbal medicines for PD.
| Study | Herbal medicines | Target cell | Herbal extraction | Dosage | Outcomes and mechanisms |
|---|---|---|---|---|---|
| Imai et al. (1995) [ | Shakuyaku-kanzo-to (TJ-68) | Human endometrium (proliferative-phase from hysterectomy patients due to leiomyoma) | Concentration: 1 to 10 mg/mL Time: 30 min | 0, 1, 10, 100, and 1000 | (1) PG level↓ |
|
| |||||
| Hsu et al. (2003) [ | Wen-Jing Tang | Uterine muscle from female Wistar rats (250–350 g) | Extract rate: 35.73%. | 0.125–4 mg/mL | Uterine contraction |
|
| |||||
| Hsu et al. (2006) [ | Dang-Qui-Shao-Yao-San | Uterine muscle from female Wistar rats (250–350 g, 6-7 weeks old) | Extract rate: 30.63%. | 0.125–4 mg/mL | Uterine contraction |
|
| |||||
| Du et al. (2006) [ | Ligustilide (from | Uterine muscle from female Wistar rats (180–200 g) and female ICR mice (20–24 g) | Purity: >97% | 2–8 | Uterine contraction |
|
| |||||
| Hua et al. (2008) [ | Dang-Gui-Shao-Yao-San | Endometrium from nonpregnant female Sprague-Dawley rats (190–210 g) | Solvent: 10 L of 50% ethanol | 1, 10, and 100 | (1) PGF2 |
|
| |||||
| Hsia et al. (2008) [ | Adlay hull | Uterine muscle from female Sprague-Dawley rats (200–300 g) | Solvent: 1 L of methanol | 0, 25, 75, 175, 375, and 500 | (1) Uterine contraction (induced by PGF2 |
|
| |||||
| Perez-Hernandez et al. (2008) [ |
| Uterine rings from virgin female Wistar rats (240–300 g) | Solvent: 3 L of hexanes | 10, 30, and 100 | Uterine contraction (induced by KCl)↓ |
|
| |||||
| Rowlands et al. (2009) [ | Bak Foong Pills | Uterine muscle from mature female ICR mice (8–10 weeks old) | Solvent: ethanol | −4.5–2.5 log mg/mL | Uterine contraction (induced by oxytocin)↓ |
|
| |||||
| Su et al. (2010) [ | Shaofu Zhuyu decoction | Uterine muscle from nonpregnant sexually mature female Kunming strain mice (18–22 g, 6-7 weeks old) | Solvent: 5 mL of methanol | 6.25–200 | Uterine contraction (induced by oxytocin)↓ |
|
| |||||
| Liu et al. (2011) [ | Xiang-Fu-Si-Wu decoction | Uterine muscle from virgin female Wistar rats (180–220 g) and female ICR mice (20–25 g) | Solvent: ethanol (10–80%) | 0.01 or 0.001 mg/mL | Uterine contraction (induced by oxytocin)↓ |
|
| |||||
| Shi et al. (2012) [ | Isoliquiritigenin (from | Uterine muscle from nonpregnant female ICR mice (18–22 g) | Purity: >99% | 0.5–1000 | (1) Uterine contraction |
|
| |||||
|
Shih and Yang(2012) [ | Wogonin (from | Uterine muscle from nonpregnant female Wistar rats (250–350 g) | Solvent: 50% aqueous ethanol | 1–100 | Uterine contraction |
|
| |||||
| Jia et al. (2013) [ | Core licorice extract (CLE) | Uterine muscle from healthy and young adult female ICR mice (25–30 g) | Concentration: 0.5 g/mL | (1) Control group: distilled water | Uterine contraction |
In vivo studies of herbal medicines for PD.
| Study | Herbal medicines | Animal model | Herbal extraction | Route of administration | Dosage and periods | Outcomes and mechanisms |
|---|---|---|---|---|---|---|
| Hsia et al. (2008) [ | Adlay hull | Female Sprague-Dawley rats at estrus stage (200–300 g) | Solvent: 1 L of methanol | Subcutaneous injection | 5 or 10 mg/kg | Uterine contraction (induced by PGF2 |
|
| ||||||
| Ma et al. (2011) [ | Shao Fu Zhu Yu decoction | Female ICR mice (18–22 g) | Solvent: 1 L of boiling water | Oral | 0.92, 1.84, and 3.68 g/kg | (1) Acetic acid-induced writhing↓ |
|
| ||||||
| Liu et al. (2011) [ | Xiang-Fu-Si-Wu decoction | Virgin female Wistar rats (180–220 g) and female ICR mice (20–25 g) | Solvent: ethanol (10–80%) | Oral | 54.60, 27.30, and 5.46 mg crude herbs/g/d | Ca2+ ↓ |
|
| ||||||
| Shi et al. (2012) [ | Isoliquiritigenin (from | Nonpregnant ICR mice (18–22 g) | Purity: >99% | Oral | 20, 40, and 80 mg/kg | (1) Acetic acid-induced writhing↓ |
|
| ||||||
| Rowlands et al. (2012) [ | Bak Foong Pills | Specified pathogen-free C57/B6 mice | — | Oral | 0.25, 0.5, 1, and 5 g/kg/day | (1) PGE2 level↓ (2) Acetic acid-induced writhing↓ |
|
| ||||||
| Su et al. (2012) [ | (1) | ICR mice (18–22 g) | Solvent: 20 L of water | Intragastric | (1) Control | (1) Paw edema (induced by formalin, carrageenan)↓ |
|
| ||||||
| Chen et al. (2013) [ |
| Virgin female Wistar rats (250–300 g) | — | Oral | (1) YHP (0.698 g/kg) | (1) SOD↑ |
|
| ||||||
| Liu et al. (2014) [ | Xiang-Fu-Si-Wu decoction | Female Sprague-Dawley rats (220–250 g) | Solvent: 80% ethanol | Oral | 3.78 g crude herbs/kg/d | (1) PG level (—) |
Herbal interventions used in 18 studies.
| Herbal intervention | Reference |
|---|---|
| Herbal compounds | |
| Isoliquiritigenin (from | [ |
| Wogonin (from | [ |
| Ligustilide (from | [ |
| Individual herbal extracts | |
| Core licorice | [ |
| Adlay hull | [ |
|
| [ |
|
| [ |
|
| [ |
| Herbal formula decoctions | |
| Dang-Gui-Shao-Yao-San (Danggui-Shaoyao-San) | [ |
| Bak Foong pills | [ |
| Xiang-Fu-Si-Wu decoction | [ |
| Shaofu Zhuyu decoction (Shao Fu Zhu Yu decoction) | [ |
| Shakuyaku-kanzo-to | [ |
| Wen-Jing Tang | [ |
|
| [ |
Frequently used herbs in herbal formula decoctions.
| Herbs | Reference |
|---|---|
|
| Nine studies [ |
|
| |
|
| Eight studies [ |
|
| |
|
| Seven studies [ |
|
| |
|
| Six studies [ |
|
| |
|
| Four studies [ |
|
| |
|
| Three studies [ |
|
| |
|
| Two studies [ |
| Rhizoma | Two studies [ |
| Radix | Two studies [ |
|
| Two studies [ |
|
| Two studies [ |
|
| Two studies [ |
|
| Two studies [ |
|
| Two studies [ |
|
| Two studies [ |
|
| Two studies [ |
|
| Two studies [ |
|
| Two studies [ |
|
| Two studies [ |
|
| Two studies [ |
|
| Two studies [ |
|
| Two studies [ |
|
| Two studies [ |
| Fructus | Two studies [ |
|
| Two studies [ |
| Pollen | Two studies [ |
| Radix | Two studies [ |
| Radix | Two studies [ |
|
| |
|
| One study [ |
|
| One study [ |
|
| One study [ |
|
| One study [ |
|
| One study [ |
|
| One study [ |
Target cells and animal models.
| Target cells ( | Reference |
|---|---|
| Human endometrium | [ |
| Uterine muscle from rats or mice | [ |
| Endometrium from rats | [ |
|
| |
| Animal models ( | Reference |
|
| |
| Estrus stage | [ |
| Induced by oxytocin following estradiol benzoate | [ |
| Induced by acetic acid | [ |
The mechanisms of herbal medicines for PD.
| Main outcomes | Reference |
|---|---|
| Inhibition of uterine contraction | [ |
| PG level reduction | [ |
| Suppression of COX-2 expression | [ |
| SOD activation and MDA reduction | [ |
| NO, iNOS, and NF- | [ |
| Stimulation of somatostatin receptor | [ |
| Intracellular Ca2+ reduction | [ |
| Recovery of phospholipid metabolism | [ |